Day One Biopharmaceuticals Inc. logo

DAWN

NASDAQ

Day One Biopharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021
$21.52+0.03 (+0.14%)
Website
News25/Ratings12

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Price$21.52+0.02 (+0.12%)
01:30 PM08:00 PM
News · 26 weeks105+94%
2025-10-26: 02025-11-02: 152025-11-09: 62025-11-16: 72025-11-23: 32025-11-30: 22025-12-07: 02025-12-14: 12025-12-21: 02025-12-28: 12026-01-04: 32026-01-11: 32026-01-18: 02026-01-25: 52026-02-01: 12026-02-08: 12026-02-15: 72026-02-22: 32026-03-01: 62026-03-08: 32026-03-15: 22026-03-22: 52026-03-29: 02026-04-05: 32026-04-12: 32026-04-19: 25
2025-10-262026-04-19
Mix6490d
  • SEC Filings24(38%)
  • Insider22(34%)
  • Other15(23%)
  • Earnings2(3%)
  • Analyst1(2%)

Latest news

25 items